目录号 | 产品详情 | 靶点 | |
---|---|---|---|
TP2085 | |||
Phosphopeptide ligand for the src SH2 domain (IC50 = 1 μM). Blocks src interactions with EGFR and FAK. | |||
T70724 | |||
GSK-2256098 HCl is a focal adhesion kinase-1 (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. | |||
T80529 | Integrin | ||
VnP-16 通过直接作用于β1整合素 (β1 integrin),激活FAK,促进成骨细胞分化和活性,加速骨形成。 | |||
T79363 | ROS Kinase | ||
APG-2449为口服活性的ALK/ROS1/FAK抑制剂,在非小细胞肺癌(NSCLC)的小鼠模型中显示出显著的抗肿瘤效果。 | |||
T63794 | |||
PND-1186 hydrochloride (VS-4718 hydrochloride) 是高特异性的、可逆的 FAK 的有效抑制剂 (IC50: 1.5 nM),能够选择性的诱导肿瘤细胞凋亡 (apoptosis)。 | |||
T63431 | |||
EGFR-IN-46 是有效的 EGFR (IC50: 20.17 nM) 和 FAK (IC50: 14.25 nM) 双重抑制剂,能够显著抑制癌细胞的生长,并诱导细胞凋亡。 | |||
T23539 | Others | ||
focal adhesion kinase (FAK) inhibitor | |||
T73094 | |||
Adhesamine 是一种哑铃状的分子,能够激活 MAPK/FAK 通路。Adhesamine 能促进哺乳动物细胞的粘附和生长。Adhesamine 加速原代培养小鼠海马神经元的分化并提高存活率。 | |||
T68740 | |||
NVP-TAC544 is a novel focal adhesion kinase (FAK) inhibitor, potently blocking kinase activity of FAK along with Aurora A, activated Cdc42-associated kinase 1 (ACK1), Met, insulin receptor (IR), TrkA, and IGF-1R. | |||
T22397 | Others | ||
PF-4618433 is a dual inhibitor of focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2). |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPH-02922 | SRPX2 Protein, Mouse, Recombinant (His & Myc) | Mouse | Baculovirus Insect Cells | ||
Acts as a ligand for the urokinase plasminogen activator surface receptor. Plays a role in angiogenesis by inducing endothelial cell migration and the formation of vascular network (cords). Involved in cellular migration and adhesion. Increases the phosphorylation levels of FAK. Interacts with and increases the mitogenic activity of HGF. Promotes synapse formation. Required for ultrasonic vocalizations. SRPX2 Protein, Mouse, Recombinant (His & Myc) is expressed in Baculovirus insect cells with N-10xHis and C-Myc tag. The predicted molecular weight is 54.5 kDa and the accession number is Q8R054.
|
|||||
TMPH-02923 | SRPX2 Protein, Mouse, Recombinant (His & Myc & SUMO) | Mouse | E. coli | ||
Acts as a ligand for the urokinase plasminogen activator surface receptor. Plays a role in angiogenesis by inducing endothelial cell migration and the formation of vascular network (cords). Involved in cellular migration and adhesion. Increases the phosphorylation levels of FAK. Interacts with and increases the mitogenic activity of HGF. Promotes synapse formation. Required for ultrasonic vocalizations. SRPX2 Protein, Mouse, Recombinant (His & Myc & SUMO) is expressed in E. coli expression system with N-10xHis-SUMO and C-Myc tag. The predicted molecular weight is 70.5 kDa and the accession number is Q8R054.
|
|||||
TMPY-03440 | Sts1 Protein, Human, Recombinant (His) | Human | E. coli | ||
UBASH3B contains a ubiquitin associated domain at the N-terminus, an SH3 domain, and a C-terminal domain with similarities to the catalytic motif of phosphoglycerate mutase. UBASH3B was found to inhibit endocytosis of epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor. UBASH3B interferes with CBL-mediated down-regulation and degradation of receptor-type tyrosine kinases. It promotes accumulation of activated target receptors, such as T-cell receptors and EGFR, on the cell surface. UBASH3B exhibits tyrosine phosphatase activity toward several substrates including EGFR, FAK, SYK, and ZAP7. Down-regulates proteins that are dually modified by both protein tyrosine phosphorylation and ubiquitination.
|
|||||
TMPY-04084 | ANGPTL1 Protein, Canine, Recombinant (hFc) | Canine | HEK293 Cells | ||
Angiopoietin-like protein 1 (ANGPTL1) has been reported to suppress migration and invasion in lung and breast cancer, acting as a novel tumor suppressor candidate. Downregulation of tumor suppressor signaling plays an important role in the pathogenesis of hepatocellular carcinoma (HCC).The downregulation of the angiopoietin-like protein ANGPTL1 is associated with vascular invasion, tumor thrombus, metastasis, and poor prognosis in HCC. Ectopic expression of ANGPTL1 in HCC cells effectively decreased their in vitro and in vivotumorigenicity, cell motility, and angiogenesis. shRNA-mediated depletion of ANGPTL1 exerted opposing effects. ANGPTL1 promoted apoptosis via inhibition of the STAT3/Bcl-2-mediated antiapoptotic pathway and decreased cell migration and invasion via downregulation of transcription factors SNAIL and SLUG. Furthermore, ANGPTL1 inhibited angiogenesis by attenuating ERK and AKT signaling and interacted with integrin α1β1 receptor to suppress the downstream FAK/Src-JAK-STAT3 signaling pathway. Taken together, these results suggest ANGPTL1 as a prognostic biomarker and novel therapeutic agent in HCC. ANGPTL1 expression was down-regulated in CRC tissues and inversely correlated with poor survival. ANGPTL1 repressed migration and invasion of CRC cells, and microRNA-138 was involved in this process. Angiopoietin-like protein 1 (ANGPTL1) has been shown to act as a tumor suppressor by inhibiting angiogenesis, cancer invasion, and metastasis.
|